TACE combined with Sorafenib or Apatinib for treatment of advanced hepatocellular carcinoma
10.13929/j.1672-8475.201907002
- Author:
Yanhong YANG
1
Author Information
1. Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University
- Publication Type:Journal Article
- Keywords:
Apatinib;
Carcinoma, hepatocellular;
Chemoembolization, therapeutic;
Sorafenib;
Vascular endothelial growth factor
- From:
Chinese Journal of Interventional Imaging and Therapy
2019;16(12):735-740
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To comparatively analyze the effect of TACE combined with Sorafenib or Apatinib in treatment of advanced hepatocellular carcinoma (HCC). Methods: Data of 73 patients with advanced HCC were retrospectively analyzed, including 41 underwent TACE combined with Sorafenib (group S) and 32 underwent TACE combined with Apatinib (group A). The therapeutic efficacy, safety and prognosis were compared between 2 groups. Results: No significant difference of object response rate (ORR) nor disease control rate (DCR) was detected between 2 groups after 1, 3, 6 and 12 months' treatment (all P>0.05). Dose adjustment occurred in 20 patients in group A mainly due to the occurrence of hand-foot syndrome, abdominal pain and loss of appetite, and drug discontinued in 9 cases among them. Meanwhile, dose adjustment happened in 6 cases of group S, mainly because of hand-foot syndrome and proteinuria, and no withdrawal occurred in group S. Before dose adjustment, adverse events (AE) in A group was less than in group S (P<0.01). After dose adjustment, no significant difference of AE was found between 2 groups (P=0.20). The progression free survival (PFS) rate of 6, 12 and 18 months was 31.25%(10/32), 6.25%(2/32) and 3.13%(1/32) of group A, respectively, while was 39.02%(16/41), 19.51%(8/41) and 9.76%(4/41) of group S (χ2=5.18, P=0.02). Conclusion: TACE combined with Sorafenib has better effect and safety for treatment of advanced HCC than TACE plus Apatinib.
